FDA advisory panel vote against approving Biogen’s drug for Alzheimer’s November 6, 2020 Auto Bot aducanumab, alzheimer's disease, Biogen, BioPharma, biopharma nl, Eisai, News, Pharma, Rhode Island 0 The nonbinding panel recommendation to reject the drug goes against what FDA scientists presented but they throw up another obstacle for the drug, which is trying to succeed on a front where others have failed.